Regencell Bioscience Holdings Limited Ordinary Shares
RGCRegencell Bioscience Holdings Limited is a biotechnology company focused on developing and commercializing traditional Chinese medicine-based products aimed at improving cognitive health and neurological conditions. The company leverages modern scientific approaches to enhance the efficacy of herbal formulations, targeting markets in Asia and globally.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| February 26, 2018 | $0.22 | 2018-02-15 | 2018-02-17 |
| December 15, 2017 | $0.22 | 2017-12-01 | 2017-12-04 |
| September 15, 2017 | $0.22 | 2017-08-31 | 2017-09-05 |
| June 15, 2017 | $0.22 | 2017-06-01 | 2017-06-05 |
| March 15, 2017 | $0.22 | 2017-03-01 | 2017-03-03 |
Dividends Summary
- Consistent Payer: Regencell Bioscience Holdings Limited Ordinary Shares has rewarded shareholders with 62 dividend payments over the past 14 years.
- Total Returned Value: Investors who held RGC shares during this period received a total of $23.76 per share in dividend income.
- Latest Payout: The most recent dividend of $0.22/share was paid 2888 days ago, on February 26, 2018.
- Yield & Schedule: RGC currently pays dividends quarterly with an annual yield of 2.86%.
- Dividend Growth: Since 2004, the dividend payout has grown by 22.2%, from $0.18 to $0.22.
- Dividend Reliability: RGC has maintained or increased its dividend for 13 consecutive payments.
Company News
Ten large-cap stocks experienced significant declines during the week of January 12-16, 2026. Regencell Bioscience led losses with a 42.08% drop, while Trip.com fell 20.19% following a Chinese anti-monopoly investigation. Other major decliners included Atlassian (19.82%), Figma (19.41%), HubSpot (16.56%), and Intuit (14.38%), with analyst downgra...
Ten large-cap stocks surged last week driven by defense spending increases, AI infrastructure deals, and acquisition speculation. Top performers included Regencell Bioscience (89.45% gain), Revolution Medicines (51.38% on Merck acquisition talks), Kratos Defense (36.12% on military budget expansion), AeroVironment (35.86% on Army partnership), Ka...
Shareholder rights law firm Bragar Eagel & Squire is investigating Regencell Bioscience and Camping World Holdings for potential federal securities law violations. Regencell disclosed a DOJ investigation into trading of its shares in October 2025, causing an 18.56% stock decline. Camping World revealed prior period misstatements related to deferr...
Regencell Bioscience, a Hong Kong-based pharma company with no revenue, surged over 17,000% in 2025 to reach a $11 billion market cap. The dramatic rise was driven by its low public float (only ~56 million of 494 million shares publicly available), social media buzz about its Traditional Chinese Medicine treatments for ADHD and autism, algorithmi...
Law firm investigating potential securities law violations for Regencell and Camping World, following DOJ investigation and financial reporting discrepancies that negatively impacted stock prices.
